Entrada Therapeutics, Inc.

Contributing Author

Recent Articles by Entrada Therapeutics, Inc.

May-28	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping TRDA GlobeNewswire
May-08	Entrada Therapeutics Reports First Quarter 2025 Financial Results TRDA GlobeNewswire